Circulation and Degradation of GIP and GLP-1

Abstract

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.

Glucagon-like peptide-1 - Glucose-dependent insulinotropic polypeptide - Gut hormone - Incretin - Dipeptidyl peptidase IV - Neutral endopeptidase 24.11

References

• 1 Buchan A M, Polak J M, Capella C, Solcia E, Pearse A G. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man.  Histochemistry. 1978;  56 37-44
• 2 Damholt A B, Kofod H, Buchan A M. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine.  Cell Tissue Res. 1999;  298 287-293
• 3 Mortensen K, Christensen L L, Holst J J, Ørskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine.  Regul Pept. 2003;  114 189-196
• 4 Eissele R, Göke R, Willemer S, Harthus H P, Vermeer H, Arnold R, Göke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man.  Eur J Clin Invest. 1992;  22 283-291
• 5 Bell G I, Santerre R F, Mullenbach G T. Hamster preproglucagon contains the sequence of glucagon and two related peptides.  Nature. 1983;  302 716-718
• 6 Lund P K, Goodman R H, Dee P C, Habener J F. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.  Proc Natl Acad Sci USA. 1982;  79 345-349
• 7 Ørskov C, Rabenhoj L, Wettergren A, Kofod H, Holst J J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.  Diabetes. 1994;  43 535-539
• 8 Mojsov S, Weir G C, Habener J F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.  J Clin Invest. 1987;  79 616-619
• 9 Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen P N, Holst J J. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum.  Am J Physiol. 2000;  278 E1010-E1018
• 10 Deacon C F, Wamberg S, Bie P, Hughes T E, Holst J J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.  J Endocrinol. 2002;  172 355-362
• 11 Ørkov C, Wettergren A, Holst J J. Biological effects and metabolic rates of glucagonlike peptide-1 7 - 36 amide and glucagonlike peptide-1 7 - 37 in healthy subjects are indistinguishable.  Diabetes.. 1993;  42 658-661
• 12 Wettergren A, Pridal L, Wojdermann M, Holst J J. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans.  Regul Pept. 1998;  77 83-87
• 13 Deacon C F, Johnsen A H, Holst J J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.  J Clin Endocrinol Metab. 1995;  80 952-957
• 14 Kieffer T J, McIntosh C H, Pederson R A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.  Endocrinology. 1995;  136 3585-3596
• 15 Pridal L, Deacon C F, Kirk O, Christensen J V, Carr R D, Holst J J. Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36) amide in dogs and is degraded more quickly in vitro by dog plasma.  Eur J Drug Metab Pharmacokinet. 1996;  21 51-59
• 16 Knudsen L B, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.  Eur J Pharmacol. 1996;  318 429-435
• 17 Pauly R P, Rosche F, Wermann M, McIntosh C H, Pederson R A, Demuth H U. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach.  J Biol Chem. 1996;  271 23222-23229
• 18 Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, Tobe T, Imura H. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor.  Proc Natl Acad Sci USA. 1987;  84 7005-7008
• 19 Tseng C C, Jarboe L A, Landau S B, Williams E K, Wolfe M M. Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat.  Proc Natl Acad Sci USA. 1993;  90 1992-1996
• 20 Burhol P G, Jorde R, Waldum H L. Radioimmunoassay of plasma gastric inhibitory polypeptide (GIP), release of GIP after a test meal and duodenal infusion of bile, and immunoreactive plasma GIP components in man.  Digestion. 1980;  20 336-345
• 21 Krarup T, Holst J J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera.  Regul Pept. 1984;  9 35-46
• 22 Krarup T, Holst J J, Larsen K L. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat.  Am J Physiol.. 1985;  249 E195-E200
• 23 Otte S C, Mutt V, McIntosh C HS, Brown J C. Purification and amino acid composition of an 8000 dalton immunoreactive form of GIP.  Dig Dis Sci. 1984;  29 (Suppl) 63S (abstract)
• 24 Jörnvall H, Carlquist M, Kwauk S, Otte S C, McIntosh C H, Brown J C, Mutt V. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP).  FEBS Lett. 1981;  123 205-210
• 25 Deacon C F, Nauck M A, Meier J, Hucking K, Holst J J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.  J Clin Endocrinol Metab. 2000;  85 3575-3581
• 26 Nauck M A, Kleine N, Ørskov C, Holst J J, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.  Diabetologia. 1993;  36 741-744
• 27 Gutniak M K, Linde B, Holst J J, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.  Diabetes Care. 1994;  17 1039-1044
• 28 Nauck M A, Wollschlager D, Werner J, Holst J J, Ørskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.  Diabetologia. 1996;  39 1546-1553
• 29 Buckley D I, Lundquist P. Analysis of the degradation of insulinotropin [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs.  Reg Pept. 1992;  40 117 (abstract)
• 30 Mentlein R, Gallwitz B, Schmidt W E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7 - 36) amide, peptide histidine methionine and is responsible for their degradation in human serum.  Eur J Biochem. 1993;  214 829-835
• 31 Adelhorst K, Hedegaard B B, Knudsen L B, Kirk O. Structure-activity studies of glucagon-like peptide-1.  J Biol Chem. 1994;  269 6275-6278
• 32 Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides.  Regul Pept. 1999;  85 9-24
• 33 Deacon C F, Nauck M A, Toft-Nielsen M, Pridal L, Willms B, Holst J J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.  Diabetes. 1995;  44 1126-1131
• 34 Deacon C F, Wamberg S, Bie P, Hughes T E, Holst J J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.  J Endocrinol. 2002;  172 355-362
• 35 Vilsboll T, Agerso H, Krarup T, Holst J J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.  J Clin Endocrinol Metab. 2003;  88 220-224
• 36 Meier J J, Nauck M A, Kranz D, Holst J J, Deacon C F, Gaeckler D, Schmidt W E, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.  Diabetes. 2004;  53 654-662
• 37 Hansen L, Deacon C F, Ørskov C, Holst J J. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.  Endocrinology. 1999;  140 5356-5363
• 38 Marguet D, Baggio L, Kobayashi T, Bernard A M, Pierres M, Nielsen P F, Ribel U, Watanabe T, Drucker D J, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.  Proc Natl Acad Sci USA. 2000;  97 6874-6879
• 39 Deacon C F, Hughes T E, Holst J J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.  Diabetes. 1998;  47 764-769
• 40 Deacon C F, Danielsen P, Klarskov L, Olesen M, Holst J J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs.  Diabetes. 2001;  50 1588-1597
• 41 Balkan B, Kwasnik L, Miserendino R, Holst J J, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.  Diabetologia. 1999;  42 1324-1331
• 42 Pedersen R A, White H A, Schlenzig D, Pauly R P, McIntosh C H, Demuth H U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.  Diabetes. 1998;  47 1253-1258
• 43 Ahrén B, Holst J J, Marensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.  Eur J Pharmacol. 2000;  404 239-245
• 44 Pospisilik J A, Stafford S G, Demuth H U, Brownsey R, Parkhouse W, Finegood D T, McIntosh C H, Pederson R A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.  Diabetes. 2002;  51 943-950
• 45 Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P A, Sandqvist M, Bavenholm P, Efendic S, Eriksson J W, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.  Diabetes Care. 2002;  25 869-875
• 46 Ahrén B, Landin-Olsson M, Jansson P A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.  J Clin Endocrinol Metab. 2004;  89 2078-2084
• 47 Hupe-Sodmann K, McGregor G P, Bridenbaugh R, Goke R, Goke B, Thole H, Zimmermann B, Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.  Regul Pept. 1995;  58 149-156
• 48 Hupe-Sodmann K, Goke R, Goke B, Thole H H, Zimmermann B, Voigt K, McGregor G P. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells.  Peptides. 1997;  18 625-632
• 49 Plamboeck A, Holst J J, Carr R D, Deacon C F. The degradation of glucagon-like peptide-1 involves both dipeptidyl peptidase IV and neutral endopeptidase 24.11 in vivo.  Regul Pept. 2004;  122 6 (Abstract)
• 50 O’Dorisio T M, Sirinek K R, Mazzaferri E L, Cataland S. Renal effects on serum gastric inhibitory polypeptide (GIP).  Metabolism. 1977;  26 651-656
• 51 Sirinek K R, O’Dorisio T M, Gaskill H V, Levine B A. Chronic renal failure: effect of hemodialysis on gastrointestinal hormones.  Am J Surg. 1984;  148 732-735
• 52 Ørskov C, Andreasen J, Holst J J. All products of proglucagon are elevated in plasma from uremic patients.  J Clin Endocrinol Metab. 1992;  74 379-384
• 53 Jorde R, Burhol P G, Gunnes P, Schulz T B. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats.  Scand J Gastroenterol. 1981;  16 469-471
• 54 Ruiz-Grande C, Alarcon C, Alcantara A, Castilla C, Lopez N ovoa, Villanueva-Penacarrillo M L, Valverde I. Renal catabolism of truncated glucagon-like peptide 1.  Horm Metab Res. 1993;  25 612-616
• 55 Deacon C F, Pridal L, Klarskov L, Olesen M, Holst J J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.  Am J Physiol. 1996;  271 E458-E464
• 56 Simonsen L. A comparison of the metabolism of GLP-1 and exendin-4 - focus on the role of the kidney. Masters thesis, Faculty of Health Sciences, University of Copenhagen 2004
• 57 Carone F A, Peterson D R, Flouret G. Renal tubular processing of small peptide hormones.  J Lab Clin Med. 1982;  100 1-14
• 58 Emmanouel D S, Jaspan J B, Rubenstein A H, Huen A H, Fink E, Katz A I. Glucagon metabolism in the rat.  J Clin Invest. 1978;  62 6-13
• 59 Hanks J B, Andersen D K, Wise J E, Putnam W S, Meyers W C, Jones R S. The hepatic extraction of gastric inhibitory polypeptide and insulin.  Endocrinology. 1984;  115 1011-1018
• 60 Chap Z, O’Dorisio T M, Cataland S, Field J B. Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs.  Dig Dis Sci. 1987;  32 280-284
• 61 Elovson J. Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins.  J Biol Chem. 1980;  255 5807-5815